C Solution

Quote





The dude that keeps trolling on Lannett board needs to get a life. Dude man quit calling people starting sh*t cuz you don't know whats up and anything since years ago when you failed selling under your manager. You have no kids or responsiblities and nonstop bug people. We have work and families to.- Geta grip and please quit calling your boy asking for info and sh^t.
 


i dont think Lannett even sells this profuct anymore. Some other company got it approved by the FDA. Genus life sciences. They are saying they’re the only fda approved version.
 






Bedrosian & Smith ran up debt by acquisitions and continued to lose sales by losing contracts. The only reason the stock went up was the amoral price increase of Digoxin.
From the NY TImes:

"Not Arthur P. Bedrosian, chief executive of Lannett Company. A generic drug maker with roughly $600 million in net sales in fiscal 2016, Lannett continues to push prices skyward on some of its offerings. And those moves are noteworthy on two accounts: First, its drugs are all off patent, meaning they are no longer proprietary formulations and should sell at deep discounts. The other: Lannett is raising prices even as it faces an antitrust inquiry from the Justice Department and a drug-pricing investigation by Connecticut’s attorney general.

Lannett, based in Philadelphia, sells drugs for thyroid conditions, gastrointestinal diseases and congestive heart failure, among other ailments. Its most recent price rise on dicyclomine, a treatment for irritable bowel syndrome, is scheduled to go into effect on May 2. A bottle of 100 10-milligram capsules will cost $19.95, up from $5.90, its price since 2001.

But that is a relatively tiny bump compared with recent price increases on its other drugs. Last year, Lannett more than tripled the price of terbutaline, a treatment for asthma and emphysema, propelling it to $435 for 100 tablets of 2.5 milligrams each, up from $136 for the bottle.

Many elderly patients take fluphenazine. Data from QuintilesIMSshows that in January, Medicare and Medicaid together covered 65 percent of prescriptions for Lannett’s version of the drug. This puts taxpayers squarely on the hook for Lannett’s price increases.

While Lannett’s customers and American taxpayers may be hurt by the company’s pricing practices, Wall Street loves them. Among the six analysts who cover the company, five rate it a “buy” and one a “perform,” or hold. Lannett’s stock was up 7.6 percent over the past week and 15 percent this year to date."
 



Write your reply...
Top Bottom
Back
Quote